• Users Online: 92
  • Print this page
  • Email this page
Year : 2020  |  Volume : 3  |  Issue : 3  |  Page : 537-544

Dabrafenib: A narrative drug review

Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India

Correspondence Address:
Lakhan Kashyap
Room No. 914, Golden Jubilee Building, Tata Memorial Hospital, Parel, Mumbai - 400 012, Maharashtra
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/CRST.CRST_210_20

Get Permissions

Activating mutations in the BRAF gene lead to an unregulated downstream signaling of the MAPK/extracellular-signal-regulated kinase pathway. This pathway is implicated in a range of solid tumors, and BRAF inhibitors are an attractive option in the treatment of these cancers. At present, three BRAF inhibitors have received the Food and Drug Administration approval for the treatment of cancer, namely, dabrafenib, vemurafenib, and encorafenib. Dabrafenib is approved for the treatment of advanced melanomas, anaplastic thyroid cancers, non-small cell lung cancers, and for the adjuvant treatment of melanomas harboring the BRAF V600E/K mutation. This review of dabrafenib describes its chemistry, pharmacokinetics, interactions, clinical indications, and safety profile. We identified and included studies from the PubMed database using search terms “dabrafenib”, “trametinib” or “pharmacology” for qualitative synthesis.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded22    
    Comments [Add]    

Recommend this journal